The effects of rosuvastatin on the serum level of hs-CRP, TNF-α, ICAM-1 in patients with the early-stage diabetic nephropathy
SONG Yan
Abstract：Objective To investigate the protection effect of statins on the early-stage type 2 diabetic nephropathy. Methods Sixty patients of early type 2 diabetics nephropathy with or without lipid abnormality were randomly divided into two groups: rosuvastatin calcium treatment group (DNR) and regular treatment group (DN).Thirty age and gender-matching healthy people were regarded as the healthy control group(NC). The glucose, lipid,creatinine, blood urea nitrogen, high-sensitivity C-reactive protein (hs-CRP) , 24 h urinary micro-albumin serum level of tumor necrosis factor(TNF)-α, cell adhesion molecules (ICAM)-1 were measured. Results Before treatment, Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), fasting blood glucose (FBS), 2-hour postprandial blood glucose (PBS), urine protein excretion rate (UAER)and CRP in DN and DNR patients were higher than those in NC patients. After treatment, the serum level of TC, LDLC, TG in patients in DNR group decreased significantly(P ＜ 0. 01). The UAER and CRP leve in DN and DNR groups decreased significantly. After the treatment, the serum level of TNF-α, ICAM-1 in DNR group and in DN group [(15.83 ±1.02) ng/L and(452.1 ± 171. 8)μg/L] also decreased significantly. Conclusions Rosuvastatin can significantly reduce the microalbuminuria excretion in diabetic nephropathy, effectively decrease the blood lipid, hs-CRP and inflammatory mediators such as TNF-α and ICAM-1 level, which indicates that statins can reduce urine protein and protect renal function by inhibiting the inflammatory process.
Keywords：Diabetic nephropathyRosuvastatinProtection mechanismInflammation
Publication Date：2011-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)